Navigation Links
Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Date:8/28/2008

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences:

BioCentury Newsmakers in the Biotech Industry

Thursday, September 4, 2008, 10:00 AM Eastern time

Millennium Broadway Hotel, New York

UBS Global Life Sciences Conference

Tuesday, September 23, 2008, 9:30 AM Eastern time

Grand Hyatt Hotel, New York

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
2. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
5. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
6. Cell Therapeutics, Inc. Announces Reverse Stock Split
7. Pixel Bridge Works With Anika Therapeutics to Launch New Website
8. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
9. Arno Therapeutics Announces Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses ... EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The ...
(Date:10/6/2017)... D.C. (PRWEB) , ... October 06, 2017 , ... ... will host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical ... Principal Investigator, Dana-Farber Cancer Institute. The event is free and open to the ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):